Enteropathy-associated T-cell lymphoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
* According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months | * According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months | ||
* The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma | * The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma | ||
* Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm<ref name= | * Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm<ref name=pmid21566094>{{cite journal |vauthors=Delabie J, etal |title=Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project|journal=Blood |volume=118|issue=148|pages= 148|date=July 2011 |doi=10.1182/blood-2011-02-335216}}</ref> | ||
* [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients | * [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients | ||
* One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)<ref name="pmid23361910"/> | * One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)<ref name="pmid23361910"/> |
Revision as of 16:39, 27 January 2016
Enteropathy-associated T-cell lymphoma Microchapters |
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
FDA on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
CDC on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis in the news |
Blogs on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Prognosis
- Recurrences most frequent in the small intestine[1]
- According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months
- The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma
- Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm[2]
- Autologous stem cell transplantation is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients
- One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)[3]
References
- ↑ Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016
- ↑ Delabie J, et al. (July 2011). "Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project". Blood. 118 (148): 148. doi:10.1182/blood-2011-02-335216.
- ↑